1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Serbia Pharmaceuticals and Healthcare Report Q1 2016

Serbia Pharmaceuticals and Healthcare Report Q1 2016

  • December 2015
  • -
  • Business Monitor International
  • -
  • 88 pages

Includes 3 FREE quarterly updates

BMI View: The Serbian pharmaceutical and healthcare market represents a challenging environment forforeign drugmakers Government cost containment, implemented through severe drug price cuts by theRFZO, will dampen growth Furthermore, an increasing reliance on private health spending will impactpharmaceutical sales as the worsening macroeconomic outlook will reduce consumer spending powerHeadline Expenditure ProjectionsPharmaceuticals: RSD9243bn (USD105bn) in 2014 to RSD9142bn (USD820mn) in 2015; -11% inlocal currency terms and -215% in US dollar terms Forecast unchanged from Q415Healthcare: RSD38948bn (USD440bn) in 2014 to RSD38491bn (USD345bn) in 2015; -12% in localcurrency terms and -216% in US dollar terms Forecasts unchanged from Q415

Table Of Contents

Serbia Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Serbia 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Serbia 2013-2019) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2013-2019) 14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2013-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2013-2019) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Serbia 2013-2019) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Serbia 2013-2019) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Serbia 2013-2019) 21
OTC Medicines Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Serbia 2013-2019) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Serbia 2013-2019) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Serbia 2013-2019) 26
Pharmaceuticals and Healthcare Risk/Reward Index 27
Central And Eastern Europe Risk/Reward Index - Q1 2016 27
Serbia Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 36
Registration Renewals 38
Intellectual Property Environment 39
Promotion 41
Pricing Regime 44
Reimbursement Regime 45
Market Overview 47
Epidemiology 48
Table: Serbian Cancer Incidence Rates, 2012-2035 49
Healthcare Sector 51
Healthcare Insurance 52
Table: Healthcare Resources (Serbia 2009-2014) 53
Table: Healthcare Personnel (Serbia 2009-2014) 53
Table: Healthcare Activity (Serbia 2009-2014) 54
Research and Development 54
Clinical Trials 55
Competitive Landscape 57
Research-Based Industry 57
Generic Drugmakers 58
Pharmaceutical Distribution 58
Pharmaceutical Retail Sector 59
Company Profile 60
GlaxoSmithKline 60
Krka 63
Merck 66
Novartis 68
Pfizer 70
Sanofi 72
Zdravlje Actavis 74
Demographic Forecast 78
Table: Population Headline Indicators (Serbia 2005-2025) 79
Table: Population By Age Group (Serbia 2005-2025) 79
Table: Population By Age Group % (Serbia 2005-2025) 80
Glossary 82
Methodology 84
Pharmaceutical Expenditure Forecast Model 84
Healthcare Expenditure Forecast Model 84
Notes On Methodology 85
Risk/Reward Index Methodology 86
Index Overview 87
Table: Pharmaceutical Risk/Reward Index Indicators 87
Indicator Weightings 88

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Opioid and Anesthetics Market in Australia

  • December 2016
    5 pages
  • Opioid  

    Anesthetics  

    Analgesic  

  • Australia  

View report >

Related Market Segments :

Pharmaceutical
Healthcare

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.